Zontivity (voraxapar) is a new type of anti-platelet medication for people who have had a heart attack, or who have reduced blood flow in their legs. It is used to reduce the risk of heart attack, stroke, cardiovascular death, and the need for procedures to restore blood flow to the heart. It was approved by the FDA in May 2014, and will be available from manufacturer Merck later this year.
When will Zontivity be available?
According to the manufacturer the anticipated availability date for this medication is the third quarter of 2014.
What type of medication is Zontivity?
Zontivity is considered a PAR-1 antagonist, a type of anti-platelet medication. Zontivity inhibits the protease-activated receptor-1 (PAR-1) which is the primary receptor for thrombin, an enzyme that causes blood clotting. By blocking this receptor, Zontivity will stop the aggregation of platelets and potentially stop a clot from forming.
Are there any other medications in this class?
No. Zontivity is the first medication in this new class, PAR-1 antagonists.
Can I take Zontivity alone?
What are the most common side effects and warnings?
Bleeding and bruising are the most common side effects, especially since Zontivity is used in combination with another anti-clotting drug. Zontivity also should not be used if you have have a stroked, mini-stroke, bleeding in your brain, or other unusual bleeding (for example, an ulcer).
Where can I find more information on Zontivity?
You can find more info and the full medication guide on the manufacturer website.